info@seagull-health.com
SeagullHealth
语言:
search
new
Indications for Seladelpar
505
Article source: Seagull Pharmacy
Oct 21, 2025

Seladelpar is a novel peroxisome proliferator-activated receptor delta (PPAR-δ) agonist, which was approved in the United States in 2024 for the treatment of primary biliary cholangitis (PBC).

Indications for Seladelpar

Primary Biliary Cholangitis (PBC)

Seladelpar is indicated for use in combination with ursodeoxycholic acid (UDCA) for the treatment of adult patients with PBC who have an inadequate response to UDCA, or as monotherapy for patients who are intolerant to UDCA.

Its indication is based on the accelerated approval process, supported by the reduction in alkaline phosphatase (ALP) levels; however, its efficacy in improving survival or reducing hepatic decompensation events has not been confirmed.

Key Limitations

Contraindicated Populations: It is not recommended for patients with decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy).

Special Warnings: Vigilance is required regarding the risk of fractures (occurring in 4% of patients in clinical trials) and abnormal liver enzymes (transaminase elevation may occur at high doses).

Specifications and Properties of Seladelpar

Dosage Form Characteristics

Specification: Hard gelatin capsules containing 10mg of active ingredient per capsule, with an opaque light gray body and a dark blue cap. The cap is imprinted with "CBAY" and the body with "10".

Composition: The active ingredient is seladelpar lysine dihydrate, and the excipients include butylated hydroxytoluene, microcrystalline cellulose, etc. The capsule shell contains gelatin, titanium dioxide, and iron oxide colorants.

Pharmacological Properties

Pharmacological Action: It inhibits CYP7A1, a key enzyme in bile acid synthesis, by activating PPAR-δ, thereby reducing bile acid accumulation.

Metabolic Characteristics: It is mainly metabolized by CYP2C9, with a half-life of approximately 6 hours. 73.4% of the drug is excreted in urine (almost entirely as metabolites).

Storage Methods for Seladelpar

Routine Storage Conditions

Temperature: Store at 20°C to 25°C (68°F to 77°F); short-term storage at 15°C to 30°C (59°F to 86°F) is permitted.

Packaging: Supplied in original high-density polyethylene bottles with child-resistant caps, containing 30 capsules per bottle.

Usage Precautions

Light and Moisture Protection: Keep the bottle cap tightly sealed to prevent the capsules from absorbing moisture or being exposed to direct sunlight.

Expiration Management: It is recommended to use the capsules within 6 months after opening the bottle. If the capsules are deformed or leaking, they should be discarded immediately.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Recommended Articles
How to Purchase Seladelpar
Seladelpar, a PPAR-δ agonist approved in 2024, is indicated for the treatment of primary biliary cholangitis (PBC) in patients who have an inadequate response to ursodeoxycholic acid (UDCA). The use o...
What Are the Side Effects of Therapeutic Agent for Vulgaris Vitiligo (Methoxsalen)?
Therapeutic Agent for Vulgaris Vitiligo (Methoxsalen) is a photosensitizer primarily used in PUVA therapy (psoralen combined with long-wave ultraviolet A irradiation) for vitiligo and psoriasis. As a ...
Precautions for Administration of Therapeutic Agent for Vulgaris Vitiligo (Methoxsalen)
As a photosensitizing drug, the therapeutic agent for vulgaris vitiligo (Methoxsalen) plays a crucial role in the PUVA therapy (photochemotherapy) for vulgaris vitiligo. This drug exerts its therapeut...
Indications for Methoxsalen (Vitiligo Vulgaris Therapeutic Agent)
Methoxsalen (a therapeutic agent for vulgaris vitiligo) is a photosensitive psoralen derivative, mainly used in PUVA (psoralen + UVA) photochemotherapy for vitiligo and psoriasis.Indications for Metho...
How to Use Seladelpar
Seladelpar is a peroxisome proliferator-activated receptor delta (PPAR-δ) agonist, which was approved in the United States in 2024 for the treatment of primary biliary cholangitis (PBC).How to Use Sel...
How to Use Therapeutic Agent for Vulgaris Vitiligo (Methoxsalen)
Therapeutic Agent for Vulgaris Vitiligo (Methoxsalen) is a photosensitive drug primarily used for treating skin diseases such as vulgaris vitiligo.How to Use Therapeutic Agent for Vulgaris Vitiligo (M...
How to Purchase Lemtrada (Alemtuzumab Injection)
Lemtrada (Alemtuzumab Injection) is a CD52-directed cytolytic monoclonal antibody used for the treatment of relapsing forms of multiple sclerosis (MS). Due to its specific safety and risk management r...
Indications for Lemtrada (Alemtuzumab Injection)
Lemtrada (Alemtuzumab Injection) is a CD52-directed cytolytic monoclonal antibody, primarily indicated for the treatment of relapsing forms of multiple sclerosis (MS). As a therapeutic drug with speci...
Related Articles
How to relieve the side effects of Gilteritinib (Xospata)?
Side effect management of Lazertinib requires targeted measures based on specific reaction types, with key focus on the prevention and control of venous thromboembolism, skin reactions, and ocular tox...
What are the side effects of Gilteritinib (Xospata)?
Gilteritinib (Xospata) is a FLT3 inhibitor. Its adverse reactions mainly involve the hematological system, cardiovascular system, digestive system, etc. Different management measures should be taken a...
Where to Buy Venetoclax Tablets
Venetoclax is a targeted medication used for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and acute myeloid leukemia (AML). As a prescription drug, its purchase a...
Indications of Venetoclax Tablets
Venetoclax is an innovative BCL‑2 inhibitor that plays an important role in the treatment of hematologic malignancies.Indications of Venetoclax TabletsMain Indications(1) Chronic Lymphocytic Leukemia ...
Side Effects of Mavacamten (Camzyos)
Mavacamten (Camzyos) is a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM), New York Heart Association (NYHA) functional cl...
What are the precautions for mavacamten (Camzyos)?
Mavacamten (Camzyos) is a novel cardiac myosin inhibitor indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) of New York Heart Association (NYHA) funct...
Mechanism of Action of Valsartan Tablets (Diovan)
Valsartan Tablets (Diovan) is a widely used angiotensin II receptor antagonist (ARB) in clinical practice, indicated mainly for the treatment of hypertension, heart failure, and reduction of cardiovas...
Important Dosage and Administration Information
As an angiotensin II receptor antagonist, valsartan is widely used in the treatment of hypertension, heart failure, and post-myocardial infarction. Appropriate selection of dosage form, dose adjustmen...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • haiousales@gmail.com
Welcome to consult
Seagull Pharmacy.,Ltd All rights reserved